Alto touts new PhIIa depression data with plans to keep charging forward
SAN FRANCISCO — Private biotech Alto Neuroscience revealed new data Tuesday morning for a psychiatric drug it’s so excited about that a follow-up study is already enrolling.
Alto touted open-label Phase IIa results for lead program ALTO-100, in which the biotech examined improvements in a depression symptom rating scale known as MADRS. Researchers compared the change in MADRS scores for patients with and without pre-defined biomarkers, and the difference proved statistically significant in both monotherapy and adjunctive cohorts.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.